Literature DB >> 9827914

Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin.

S Panneerselvam1, C Baglin, W Lefort, T Baglin.   

Abstract

A cohort of patients with an INR >7.0 were identified prospectively and compared with a group of patients with stable anticoagulant control. During the study 15,100 INR measurements were recorded and 31 (0.2%) were >7.0. Odds ratios of patient characteristics were calculated as an estimate of relative risk for the development of a high INR. The highest risk factor was a target INR of 3.5 (OR 7.3, 95% CI 2.6-20.2). The second highest risk factor was antibiotic therapy in the 4 weeks preceding the high INR (OR 6.2, 95% CI 1.4-27.7). Bleeding was reported more frequently in the high INR group (OR 5.4, 95% CI 2.1-13.9). Five major bleeds occurred in this group compared to none in the stable group. This analysis identifies risk factors for over-anticoagulation and hence when to intensify monitoring and when to consider pre-emptive warfarin dose reductions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827914     DOI: 10.1046/j.1365-2141.1998.00988.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Suprachoroidal haemorrhage after addition of clarithromycin to warfarin.

Authors:  S S Dandekar; D A Laidlaw
Journal:  J R Soc Med       Date:  2001-11       Impact factor: 5.344

2.  Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.

Authors:  Edith A Nutescu; Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

3.  The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.

Authors:  Jeffrey J Glasheen; Randolph V Fugit; Allan V Prochazka
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

4.  Interaction of antibiotics and warfarin in pediatric cardiology patients.

Authors:  M C Johnson; M Wood; V Vaughn; L Cowan; A M Sharkey
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

5.  Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics.

Authors:  Jonas Wallvik; Anders Själander; Lars Johansson; Orjan Bjuhr; Jan-Håkan Jansson
Journal:  Scand J Prim Health Care       Date:  2007-06       Impact factor: 2.581

Review 6.  Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management.

Authors:  Eric Pautas; Isabelle Gouin-Thibault; Matthieu Debray; Pascale Gaussem; Virginie Siguret
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing.

Authors:  John F Carlquist; Jason T McKinney; Zachary P Nicholas; Jessica L Clark; Samera F Kahn; Benjamin D Horne; Joseph B Muhlestein; Heidi T May; Jeffrey L Anderson
Journal:  J Thromb Thrombolysis       Date:  2007-07-29       Impact factor: 2.300

8.  Emergency department ultrasound diagnosis of spontaneous iliopsoas haemorrhage in a patient on warfarin.

Authors:  Devesh Sharma; Ramy Saker; Abha Govind
Journal:  BMJ Case Rep       Date:  2013-11-15

9.  Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?

Authors:  Mike Greaves
Journal:  PLoS Med       Date:  2005-10-25       Impact factor: 11.069

Review 10.  Coagulation assessment with the new generation of oral anticoagulants.

Authors:  Charles V Pollack
Journal:  Emerg Med J       Date:  2015-05-18       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.